背景:由于COVID-19迅速发展到严重和关键阶段,成千上万的患者需要使用重症监护病房(ICU)治疗,给卫生系统带来过度压力。沃顿胶质间充质干细胞(WJ-MSCs)的免疫调节作用在治疗COVID-19患者中显示出可喜的结果。然而,尚未描述及时应用细胞疗法对动态患者预后的影响。本病例报告介绍了多病例的临床结果,类固醇过敏,COVID-19患者接受WJ-MSCs移植治疗。
方法:一名67岁女性患有2型糖尿病,超重(82公斤,168厘米,BMI=29.053),高血压(60/190mmHg)和类固醇超敏反应,在出现典型症状如疲劳后,COVID-19检测呈阳性,胸痛,肌痛,鼻塞,熟食症,缺氧和氧饱和度(SpO2)94%-96%,体温正常(36°C)。患者接受了药物治疗,但是,当症状恶化时,移植WJ-MSC以调节细胞因子释放综合征的疑似发作。观察到症状和临床参数(炎症标志物和CT评分)的显着改善,患者在短时间内完全康复。
结论:本病例报告显示,使用沃顿的果冻间充质干细胞(WJ-MSCs)作为COVID-19的门诊和辅助治疗具有良好的结果。在COVID-19感染护理中,及时输注WJ-MSCs可以是一种安全的门诊辅助治疗,防止疾病进展到关键阶段,避免医院过度拥挤。
BACKGROUND: Due to the rapid progression of COVID-19 to severe and critical stages, thousands of patients have required the use of intensive care unit (ICU) treatment, placing an excessive strain on health systems. Immunomodulatory effects of Wharton\'s Jelly Mesenchymal Stem Cells (WJ-MSCs) have shown promising results in the treatment of patients with COVID-19. However, the effect of promptly applied cell therapy on ambulatory patient prognosis has not been described. This
case report presents the clinical outcome of a multimorbid, steroid-hypersensitive, COVID-19 patient treated with WJ-MSCs transplantation.
METHODS: A 67-year-old woman with Type 2 diabetes, overweight (82 kg, 168 cm, BMI = 29.053), hypertension (190/60 mmHg) and steroid-hypersensitivity, tested positive for COVID-19 after presenting typical symptoms such as fatigue, chest pain, myalgia, nasal congestion, dysgeusia, anosmia and oxygen saturation (SpO2) 94% - 96%, with normal body temperature (36°C). The patient received pharmacologic treatment but, when symptoms worsened, WJ-MSCs were transplanted to modulate the suspected onset of the cytokine release syndrome. Significant improvement of symptoms and clinical parameters (inflammatory markers and CT score) was observed, and the patient fully recovered within a short period of time.
CONCLUSIONS: The present
case report exhibits the favorable outcome of using Wharton\'s Jelly Mesenchymal Stem Cells (WJ-MSCs) as an ambulatory and adjuvant therapy for COVID-19. Prompt WJ-MSCs infusion can be a safe ambulatory adjuvant therapy in COVID-19 infection care, preventing disease progression to critical stages and avoiding hospital overcrowding.